TERN Biotechnology · Clinical-stage · Oncology · Obesity · Thesis updated June 14, 2026

TERN is now an oncology-first bet

TERN now plans to spend its own cash mainly on TERN-701, an oral CML cancer drug.
The company will not advance TERN-601 beyond the current Phase 2 obesity trial on its own.
TERN-601 Phase 2 FALCON data are expected early in Q4 2025.
TERN-701 CARDINAL expansion data are expected in Q4 2025, with a possible approval endpoint read-through.
Cash is expected to fund planned work into 2028, but the company remains pre-revenue.

01 Running thesis

The story narrowed

Terns used to look like a two-shot biotech: one shot in CML, a blood cancer called chronic myeloid leukemia, and one shot in obesity. That changed. The company says it will not take TERN-601, its oral GLP-1 obesity drug, past the current Phase 2 trial by itself, no matter what the data show.

The bull case is cleaner now. Terns can save cash by avoiding the huge trials and sales force needed in obesity. That lets it focus on TERN-701, an oral allosteric BCR-ABL inhibitor for CML. Allosteric means the drug binds a different spot on the target protein than many older drugs do.

The bear case is also sharper. If TERN-701 does not look strong enough against asciminib and other CML drugs, the core story weakens fast. The obesity pipeline becomes more of a partner-dependent option than a program Terns controls from start to finish.

The next proof points are specific. Investors need to see TERN-601 FALCON 12-week weight-loss data early in Q4 2025, a possible metabolic partnership, and TERN-701 CARDINAL safety and efficacy data in Q4 2025.

Aug 2025→Terns made a major strategy shift. It will not advance TERN-601 beyond the current Phase 2 trial on its own, and will focus capital on TERN-701 while seeking partners for metabolic assets.

May 2025→Lead programs stayed on track, with TERN-701 dose expansion started and both TERN-701 and TERN-601 data still expected in Q4 2025. The company also added a new FDA disruption risk.

Mar 2025→The 2024 10-K confirmed the Phase 2 FALCON trial start for TERN-601 and a Q4 2025 data plan for TERN-701. It also added supply chain risk tied to possible BIOSECURE Act limits.

Nov 2024▲TERN-601 Phase 1 obesity data showed 4.9% placebo-adjusted mean weight loss over 28 days at the highest dose. A $161.9 million net financing extended cash runway into 2028.

Aug 2024→The initial view framed Terns as a pre-revenue biotech with key shots in CML and obesity. At that point, the story depended on upcoming clinical data and cash was expected to last into 2026.

02 Business model

No sales yet, two paths

Terns is a clinical-stage drug developer. It does not sell approved products today. Its spending is funded by cash raised from investors and, potentially, economics from its TERN-701 license with Hansoh in Greater China.

The internal path is oncology. Terns plans to use its own capital to move TERN-701 through clinical development toward possible approval and commercial sales.

The partner path is metabolism. TERN-601, TERN-501, and the TERN-800 series are now assets Terns wants someone else to help fund, license, or develop. A good deal could bring cash without selling more stock, but a weak deal would cap the upside.

The model breaks if trials miss, regulators slow the process, or partners decide the obesity assets are not worth the cost of late-stage development.

03 Product portfolio

Four shots in the pipeline

Growth engine

TERN-701

TERN-701 is an oral allosteric BCR-ABL inhibitor for chronic myeloid leukemia. The Phase 1 CARDINAL dose expansion is ongoing, with more safety and efficacy data expected in Q4 2025.

Option

TERN-601

TERN-601 is an oral GLP-1 receptor agonist for obesity. The Phase 2 FALCON trial completed enrollment, and Terns plans to seek a partner rather than fund later trials on its own.

Option

TERN-501

TERN-501 is a THR-beta agonist that could fit with GLP-1 drugs in obesity or other metabolic diseases. Terns is looking for a strategic partner to move it forward.

Option

TERN-800 series

The TERN-800 series is a discovery-stage GIPR antagonist program for obesity. It is early and also sits in the partner-seeking metabolic group.

04 Business segments

One reported segment

Drug candidate research and development100%flat

Other reported segments0%flat

Terns reports one business segment: discovery, research, and development of drug candidates. The structured mix below reflects the Q2 2025 filing view, with no separate revenue-producing segment disclosed.

05 Risk factors

What can break the case

TERN-701 does not beat the bar

High impact · Medium odds

The company is now much more dependent on one lead oncology asset. The key question is whether CARDINAL expansion data show a six-month major molecular response rate, a blood marker of CML control, that can compete with asciminib. If the result is only average, a pivotal trial may be harder to justify.

We watchQ4 2025 CARDINAL expansion data, especially six-month major molecular response and safety at the chosen dose.

TERN-601 cannot attract a strong partner

High impact · Medium odds

Terns says it will not advance TERN-601 beyond Phase 2 by itself. That saves cash, but it also makes the obesity asset depend on outside demand. Even good 12-week data may not be enough if tolerability, dosing, or competitive weight loss looks weak.

We watchEarly Q4 2025 FALCON top-line data and any disclosed partnership terms for TERN-601 or other metabolic assets.

Cash lasts, but dilution risk returns

Medium impact · Medium odds

Terns says existing cash can fund planned operating expenses and capital needs into 2028. That runway helps, but the company is pre-revenue and clinical trials can become more expensive. If TERN-701 needs larger studies or a partner deal is delayed, future stock sales could return.

We watchQuarterly cash balance, operating cash burn, and whether management keeps the runway into 2028.

FDA delays slow decisions

Medium impact · Medium odds

The Q1 2025 filing added a risk about FDA disruptions from funding cuts, staff losses, regulatory reform, and shutdowns. Terns needs timely feedback on trial design and future submissions. Delays could push out key milestones even if the science works.

We watchCompany comments on FDA meeting timing, written feedback, trial amendments, or submission review delays.

China supply chain rules tighten

Medium impact · Medium odds

The 2024 10-K added risk tied to possible U.S. laws such as the BIOSECURE Act. Terns uses Chinese contract development and manufacturing organizations. If new rules restrict those partners, the company may need to shift suppliers, which can cost time and money.

We watchFinal BIOSECURE Act language or similar laws, plus any Terns disclosure about changing manufacturers.

06 Quick answers

In one breath

Is Terns Pharmaceuticals profitable?

No. Terns is pre-revenue and clinical-stage, so it spends money to run trials and develop drug candidates. Its cash runway is expected to fund planned work into 2028.

What is the main TERN stock catalyst?

The main internal catalyst is TERN-701 CARDINAL expansion data expected in Q4 2025. TERN-601 obesity Phase 2 data, expected early in Q4 2025, also matter because they could support a partnership.

Why did Terns stop self-funding the obesity program?

Management said late-stage obesity trials and the sales force needed to sell an obesity drug would take too much time and money. The company plans to focus its own capital on TERN-701 in CML and seek a partner for obesity assets.

What does TERN-701 treat?

TERN-701 is being developed for chronic myeloid leukemia, or CML. CML is a blood cancer, and TERN-701 aims to block BCR-ABL, a protein that helps drive the disease.